Researchers at Auburn University, in partnership with the University of Basel and ETH Zurich, have made a significant breakthrough in cancer research. By combining artificial intelligence (AI) with molecular dynamics simulations, they have improved the prediction of binding sites on the PD-L1 protein. This innovation could accelerate the development of personalized cancer treatments by identifying critical interaction points in cancer-related proteins. The team’s findings, published in the Journal of the American Chemical Society, focus on enhancing immunotherapies by understanding how therapeutic proteins interact with PD-L1. Their integrated approach shows promise in developing personalized therapies for cancer patients and showcases the importance of computational tools in advancing cancer therapeutics.
Source link
Auburn University researchers develop AI-driven method to target cancer proteins
